The [2020 International Conference on Translational Medicine and Advanced Therapeutic Medicine] was co-organized by the Chinese Medical Association and Taipei Veterans General Hospital and co-organized by the Taiwan-Japan Relations Association Science and Technology Exchange Committee, the Biotechnology Development Center and the Ministry of Economic Affairs Biomedical Promotion Group. Experts in the field of cell therapy at home and abroad were invited to this conference: Professor Shin Kawamata the Director of Cell Therapy Research and Development Center of the Kobe Biomedical Research and Innovation Foundation, and Wei Guang Ji, Deputy CEO of the Biotechnology Development Center (DCB), Dr. Tang Yi Ning from the Pharmaceutical Inspection Center of the Consortium, Guo Zheng Yi, Deputy General Manager of Yu Yue pf Biomedical Co., Ltd., and Gao Zhi Ping, Director of the Department of Hematology, Taipei Veterans General Hospital, gathered together to share the CAR-T treatment in Japan and Taiwan The latest progress and their respective cutting-edge clinical research results.
(Group photo of VIPs)
Cancer Cellular Immunotherapy (CAR-T) is a trend of international innovative medical development, and it is also the development focus of the Ministry of Health and Welfare, especially after the formulation of the "Administrative Measures for the Implementation or Use of Specific Medical Technology Inspection Instruments" and the "Regulations on Regenerative Medicine Preparations", The development of cancer immune cell therapy is urgent. In recent years, the Japanese government has vigorously promoted the industrialization of regenerative medicine, which has led to the rapid development of regenerative medicine research and industry in Japan, and today holds a leading position in the world. Professor Shin Kawamata of the Cell Therapy Research and Development Center of the Kobe Biomedical Research and Innovation Foundation, Japan, shared his experience with the audience in Taiwan's conference via video in Japan. As the trend of personalized therapy develops, establishing stability. Japan's industrial supply chain has become an important issue, and it illustrates the latest progress in the treatment of CAR-T in Japan. This seminar was held on December 1, 109 (Tuesday) in the first meeting room on the Zhi De Building, Taipei Veterans General Hospital. It will help accelerate CAR-T development in Taiwan and deepen cooperation and exchanges between Taiwan and Japan. The audience actively participated in the discussion, and the content is brilliant!
(Group photo of VIPs and Guests)
(Welcome speech by VIPs)
(Speech by CAR-T expertise)